Akanda Corp. AKAN PHARMA
Company Overview
Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -53.8%, profit CAGR -97.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -53.82% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -97.21% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -96.60% |
| 6 Months: | -13.42% |
| 3 Months: | -77.61% |
| 1 Month: | -36.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -53.8% CAGR over 5 years.
- Earnings shrank at -97.2% CAGR over 5 years.
- Trading 97.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AKAN Akanda Corp. PHARMA | 3.28 | -0.00 | $1.77M | 0.00% | - | - | -53.82% | -97.21% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 2.62M | 423.68K | 0 | 258.07K |
| Cost of Revenue | -649.88K | 364.35K | 0 | 414.10K |
| Gross Profit | 3.27M | 59.34K | 0 | -156.02K |
| Operating Expenses | 23.45M | 3.72M | 4.03M | 4.83M |
| Operating Income | -20.18M | -3.66M | -4.03M | -4.98M |
| EBITDA | -4.36M | -3.38M | -3.09M | -46.01M |
| Interest Expense | 115.32K | 121.40K | 81.08K | 925.09K |
| Pretax Income | -8.24M | -3.71M | -3.31M | -47.37M |
| Tax Provision | - | - | - | - |
| Net Income | -11.66M | -32.28M | -4.10M | -45.65M |
| Diluted EPS | -18,955.57 | -32,275.07 | -140.67 | -14,899.95 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 39.00M | 8.84M | 7.91M | 6.20M |
| Current Assets | - | 3.82M | 1.81M | 5.06M | 3.60M |
| Cash & Equivalents | - | 228.79K | 82.82K | 3.84M | 503.56K |
| Inventory | 0 | 1.87M | 1.29M | 0 | - |
| Receivables | - | 720.09K | 155.78K | 356.11K | 97.63K |
| Total Liabilities | - | 12.10M | 12.67M | 3.64M | 18.19M |
| Current Liabilities | - | 9.35M | 10.17M | 3.64M | 6.20M |
| Long Term Debt | - | 2.63M | 2.50M | - | 11.78M |
| Total Debt | - | 3.90M | 4.00M | 352.81K | 14.24M |
| Total Equity | - | 26.90M | -3.83M | 4.28M | -10.79M |
| Shares Outstanding | - | 615 | 1.00K | 29.12K | 440.77K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -11.47M | -1.50M | -3.98M | -6.73M |
| Investing Cash Flow | - | -4.22M | 24.89K | -1.02M | -7.45M |
| Financing Cash Flow | - | 14.14M | 1.49M | 8.99M | 11.68M |
| Capital Expenditure | - | -310.95K | -1.50K | -2.10M | -1.23M |
| Free Cash Flow | - | -11.78M | -1.50M | -6.08M | -7.96M |
| Net Change in Cash | - | -1.55M | 10.88K | 3.99M | -2.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 124.8% | 14.0% | - | -60.5% |
| Operating Margin % | -770.2% | -863.6% | - | -1,931.0% |
| Net Margin % | -445.0% | -7,617.7% | - | -17,690.2% |
| ROE % | -43.3% | 842.9% | -95.8% | 423.3% |
| ROCE % | -68.1% | 274.7% | -94.2% | 130,798.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.04% | 205 | $660 |
| 2 | Morgan Stanley | - | 2 | $6 |
| 3 | Wells Fargo & Company | - | 13 | $41 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AKAN
Akanda’s First Towers & Fiber Generates First Cash Flow From 200 KM Fiber Network
Akanda (NASDAQ:AKAN) subsidiary First Towers & Fiber has collected its first cash lease payment from a new 200-kilometer fiber network in Mexico, marking the shift from network construction to recurring revenue generation as the business di…
First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client
Toronto, Ontario--(Newsfile Corp. - September 4, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Me…
Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexi…
Akanda Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (…
Why Is AKAN Stock Surging Today?
The company regained compliance with Nasdaq after filing its annual report with the Securities and Exchange Commission.
Akanda Shares Surge After Restoring Nasdaq Compliance (AKAN)
Akanda Corp. (NASDAQ:AKAN) shares climbed 22% in premarket trading on Friday after the company announced it had regained compliance with Nasdaq’s listing requirements following the submission of its delayed annual report.…
AKAN — Frequently Asked Questions
What is the current share price of Akanda Corp. (AKAN)?
As of 2026-09-19 21:16 PDT, Akanda Corp. (AKAN) trades at $3.28 on NasdaqCM. Its 52-week range is $2.68 to $107.43.
What is the market capitalisation of AKAN?
Akanda Corp. (AKAN) has a market capitalisation of $1.77M on NasdaqCM.
Is AKAN a good stock to buy?
This page provides a data-driven analysis of Akanda Corp. (AKAN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.